Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AstraZeneca Files Sipavibart for COVID-19 Prevention in Japan
July 29, 2024
- EU Regulator Rejects Leqembi, Eisai to Seek Re-Examination
July 29, 2024
- Chugai’s H1 Profit Marks 2-Digit Growth on Export to Roche Despite Lower Sales
July 26, 2024
- Takeda Will Stage Recovery at Home after 4 Drug Launches in FY2024: Japan Head
July 26, 2024
- Merck, GTRI Tie Up in Development of Parkinson’s Gene Therapy
July 26, 2024
- Intage, Niigata University Tie Up on Megalin Antagonist Development
July 26, 2024
- Global Pharma Market Grows Double Digit in 2023, Humira Stays Atop Drug Ranking: IQVIA
July 26, 2024
- Amazon Launches Online Pharmacy Service in Japan
July 25, 2024
- Novo, Mitsubishi Logistics to Launch Pilot Drug Transport Using Electric Truck
July 25, 2024
- Nichi-Iko to Join Forces with Kyowa in Generic Production, Eyeing Reorganization
July 24, 2024
- Moderna, University of Tokyo Link Arms on mRNA Technology
July 24, 2024
- Kobayashi Pharma Replaces Management after Beni-Koji Scandal
July 24, 2024
- Axcelead-Teijin JV Anticipates Synergies in Common Disease Areas, Pipelines
July 23, 2024
- Astellas, Osaka University Join Hands in Cell Therapy Research
July 23, 2024
- MSD Seeks Japan Nod for RCC Med Belzutifan
July 23, 2024
- Mochida Files Pediatric Dosage of UC Drug Lialda in Japan
July 23, 2024
- Chugai to Offload Hyperammonemia Drug to Maruishi
July 23, 2024
- Terumo to End Sale of HeartSheet after Panel’s Thumbs-Down
July 22, 2024
- Deciphera’s TGCT Drug Accepted for Review in Europe: Ono
July 22, 2024
- FDA Clears IND for Japan JV’s Peptide-Based COVID Therapy
July 19, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…